HANSHOW
13.6.2024 11:51:29 CEST | Business Wire | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESL) and digital retail solutions, proudly participated in the first NRF Big Show 2024 Asia Pacific, held in Singapore from June 11-13. Organized by the National Retail Federation (NRF), this highly anticipated event marked a significant milestone in the retail industry, bringing together the best and brightest minds from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612653287/en/
Hanshow at NRF APAC 2024 (Photo: Business Wire)
A Leap Forward in Shopper Experience and Store Operation
At this prestigious event, Hanshow introduced its Smart Cart Solution, developed with Microsoft on the Azure Open AI platform, leveraging Generative AI (GenAI) to enhance customer experience and store operations in a smarter, more connected retail ecosystem. This solution featured an AI copilot for personalized shopping, offering tailored recommendations and syncing online and in-store customer profiles for a seamless shopping experience.
Additionally, the Smart Cart enables skip-the-line checkout for faster, more convenient transactions. Retailers benefited from retail media revenue by displaying location-based advertisements and offering smart product recommendations, boosting their revenue. The solution also provided valuable data on shopper behavior and product performance.
In addition, Hanshow’s Lumina digital display series revolutionizes in-store marketing by integrating with GenAI, providing a state-of-the-art digital marketing solution. With the power of GPT-4 and DALL-E3, users can effortlessly craft product POP posters, atmospheric marketing visuals, and persuasive product copy through simple text commands.
"Our co-innovated solutions with Microsoft, showcased at this NRF, mark a significant step in revolutionizing the retail experience," said Shiguo Hou, CEO of Hanshow. "Together, we are not only redefining shopping but also empowering retailers with the tools to excel in a competitive landscape and forge a shared vision for the future. We’re honored to have jointly held our Retail Conference with Microsoft in Singapore, and our meeting with Microsoft APAC CEO Ahmed Mazhari discussed yielded new areas for possible future cooperation."
Sustainability and Growth Vision
Hanshow's vision for a greener future in retail outlines the steps businesses must take to balance decarbonization and sustainability with creating value for customers, employees, and stakeholders. A key component of this vision is the electronic shelf label (ESL) solution, which transforms retail operations by enabling dynamic pricing, real-time promotions, and efficient inventory management. ESLs help retailers significantly reduce their carbon footprint by minimizing food waste and enhancing resource efficiency.
Additionally, Hanshow has expanded its offerings with a digital energy solution. Key aspects of this solution include globally integrated local teams, R&D innovation, 24/7 butler service, a one-stop turnkey PV digital energy system, and flexible financing options with PPA resources. These initiatives drive sustainability and business growth by providing tailored PV, charging, and digital energy management systems.
Hanshow’s participation in NRF APAC underscored its commitment to driving innovation in the retail sector and supporting the digital transformation of retailers worldwide. The hands-on experience provided to attendees was a glimpse into a future where our technology is the cornerstone of a more intelligent, efficient, and eco-friendly retail landscape. As we move forward, Hanshow is committed to continuing to lead and support the global retail community in embracing transformative digital solutions that shape a sustainable and prosperous tomorrow.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612653287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom